Results 231 to 240 of about 27,180,319 (308)
Automatic speech analysis for detecting cognitive decline of older adults. [PDF]
Huang L, Yang H, Che Y, Yang J.
europepmc +1 more source
Assessing the Clinical and Functional Status of COPD Patients Using Speech Analysis During and After Exacerbation. [PDF]
Mayr W +4 more
europepmc +1 more source
ABSTRACT Background Biallelic FIG4 variants classically cause distinct conditions characterized by peripheral neuropathy (Charcot‐Marie‐Tooth disease type 4J) or skeletal dysplasia (Yunis‐Varón syndrome). However, central nervous system involvement is increasingly recognized. The prevalence and specific characteristics of movement disorders within FIG4‐
Andrea Gangfuß +22 more
wiley +1 more source
Developing a Multimodal Screening Algorithm for Mild Cognitive Impairment and Early Dementia in Home Health Care: Protocol for a Cross-Sectional Case-Control Study Using Speech Analysis, Large Language Models, and Electronic Health Records. [PDF]
Zolnoori M.
europepmc +1 more source
ABSTRACT Objective Inherited ataxias are clinically diverse neurodegenerative diseases, complicating the choice of outcome measures for trials. In spinocerebellar ataxia (SCA), regulatory concerns about the Scale for the Assessment and Rating of Ataxia (SARA) caused a shift toward functional SARA (f‐SARA), contributing to pivotal trial failure.
Christian Rummey +52 more
wiley +1 more source
Protocol for detection and monitoring of post-stroke cognitive impairment through AI-powered speech analysis: a mixed methods pilot study. [PDF]
Shankar R +3 more
europepmc +1 more source
Myostatin/Smad3 in Spinal Muscular Atrophy: Biomarkers of Disease Severity and Treatment Response
ABSTRACT Objective Given the role of Myostatin (MSTN) in muscle homeostasis and its modulation by current spinal muscular atrophy (SMA) therapies, we investigated serum MSTN and, for the first time, its downstream effector Smad3 as candidate non‐invasive biomarkers in SMA patients undergoing disease‐modifying therapies (DMTs).
Giorgia Riolo +11 more
wiley +1 more source
ABSTRACT Background Blood‐based biomarkers are increasingly used to identify Alzheimer's disease (AD) pathology and may play an important role in early disease screening and participant selection for clinical trials. However, their performance across stages of cognitive impairment remains unclear. This study examined whether plasma biomarkers differ in
Maryam Abdolmaleki +7 more
wiley +1 more source

